| Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma |
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment |
|
|
| Not yet recruiting | 4 | 75 | | | Auckland District Health Board, Auckland District Health Board | Hepatitis C | | | | |
2016-003607-59: An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection. Studio in aperto per valutare i risultati a lungo termine con Ombitasvir-paritaprevir-Ritonavir e Dasabuvir, con o senza ribavirina (RBV) sulla funzione ovarica delle donne in et¿ fertile con epatite cronica HCV-positiva, genotipo 1 e 4 . |
|
|
| Terminated | 4 | 50 | Europe | VIEKIRAX, EXVIERA, 043841, Film-coated tablet, VIEKIRAX - 12,5MG/75MG/50MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA), EXVIERA - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA) | DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE, ABBVIE SRL | Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Epatite cronica HCV-positiva, genotipo 1 e 4, Hepatitis C EPATITE C, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02461745: Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO |
|
|
| Completed | 4 | 200 | US | ombitasvir, paritaprevir/r, dasabuvir + ribavirin, VIEKIRA PAK + RBV, ombitasvir, paritaprevir/r, dasabuvir, VIEKIRA PAK | Kaiser Permanente, AbbVie | Hepatitis C, Chronic | 05/17 | 05/17 | | |
| Completed | 4 | 46 | RoW | PTV/r/OBV/DSV, Viekirax/Exviera | National Taiwan University Hospital, AbbVie | Hepatitis Viruses | 10/18 | 12/18 | | |
| Completed | 4 | 1275 | US | SOF/LDV (sofosbuvir/ledipasvir), Harvoni® (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), Viekira Pak/Viekira, EBR/GZR (elbasvir/grazoprevir), Zepatier, Ribavirin, RBV | University of Florida, Patient-Centered Outcomes Research Institute, Merck Sharp & Dohme LLC, AbbVie | Chronic Hepatitis C | 06/19 | 09/20 | | |
NCT02946034: Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C |
|
|
| Completed | 4 | 10 | US | Viekira Pak ± ribavirin, AbbVie 3D regimen, Mavyret | Massachusetts General Hospital, AbbVie | Chronic Kidney Disease, Chronic Hepatitis C | 09/20 | 09/20 | | |
